EVALUATION OF THE EFFECTIVENESS OF THE DRUG "GENFERON-LITE" IN ACUTE BRONCHIOLITIS IN CHILDREN

Abstract

This article is devoted to the problem of acute bronchiolitis (OB) in children. The urgency of this problem is beyond doubt: according to the most conservative estimates, more than 150 million cases of bronchiolitis are registered worldwide every year, 7-13% of which require inpatient treatment, and 1-3% require hospitalization in the intensive care unit. The peak incidence occurs in children aged 3 to 9 months. The most common etiological factor is viruses - respiratory syncytial (the vast majority of cases - 90%), a significant agent is rhinovirus, as well as influenza A and B viruses, parainfluenza, adenovirus, coronavirus, metapneumovirus and human bokavirus. The development of bronchiolitis in children of the first two years of life can cause a number of factors. Bronchiolitis is especially severe in premature infants, children on artificial feeding, as well as in patients with congenital malformations and immunodeficiency. The article presents the experience of clinical use of Genferon Light suppositories in the treatment of patients with this pathology, taking into account its antiviral, antibacterial and immunomodulatory effects.